Stock Track | Alvotech Shares Plummet 7.68% After Q3 Revenue Miss and Lowered Guidance

Stock Track11-13

Shares of Alvotech (NASDAQ: ALVO) plunged 7.68% on Wednesday following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million.

Despite reporting a 24% increase in nine-month revenue to $420 million, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million. Adding to investor concerns, Alvotech highlighted ongoing issues from an FDA inspection of its Reykjavik facility in July as a "top priority," although the facility remains FDA approved and continues production.

The sharp stock decline also reflects apprehension over Alvotech's cash position, which decreased to $42.8 million as of September 30. This reduction was attributed to inventory build-up for new launches, capital expenditures, and recent acquisitions. While the company secured a new $100 million working capital option to address these needs, the cash burn rate appears to be worrying investors. Despite these challenges, Alvotech reported positive developments, including new biosimilar approvals in Japan and Europe, which may provide growth opportunities in the future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197124717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197124717","market":"us","top_or_hot":-1,"title":"Stock Track | Alvotech Shares Plummet 7.68% After Q3 Revenue Miss and Lowered Guidance","media":"Stock Track","content":"<p>Shares of Alvotech (NASDAQ: ALVO) plunged 7.68% on Wednesday following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million.</p>\n\n<p>Despite reporting a 24% increase in nine-month revenue to $420 million, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million. Adding to investor concerns, Alvotech highlighted ongoing issues from an FDA inspection of its Reykjavik facility in July as a \"top priority,\" although the facility remains FDA approved and continues production.</p>\n\n<p>The sharp stock decline also reflects apprehension over Alvotech's cash position, which decreased to $42.8 million as of September 30. This reduction was attributed to inventory build-up for new launches, capital expenditures, and recent acquisitions. While the company secured a new $100 million working capital option to address these needs, the cash burn rate appears to be worrying investors. Despite these challenges, Alvotech reported positive developments, including new biosimilar approvals in Japan and Europe, which may provide growth opportunities in the future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alvotech Shares Plummet 7.68% After Q3 Revenue Miss and Lowered Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alvotech Shares Plummet 7.68% After Q3 Revenue Miss and Lowered Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 13:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Alvotech (NASDAQ: ALVO) plunged 7.68% on Wednesday following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million.</p>\n\n<p>Despite reporting a 24% increase in nine-month revenue to $420 million, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million. Adding to investor concerns, Alvotech highlighted ongoing issues from an FDA inspection of its Reykjavik facility in July as a \"top priority,\" although the facility remains FDA approved and continues production.</p>\n\n<p>The sharp stock decline also reflects apprehension over Alvotech's cash position, which decreased to $42.8 million as of September 30. This reduction was attributed to inventory build-up for new launches, capital expenditures, and recent acquisitions. While the company secured a new $100 million working capital option to address these needs, the cash burn rate appears to be worrying investors. Despite these challenges, Alvotech reported positive developments, including new biosimilar approvals in Japan and Europe, which may provide growth opportunities in the future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVO","symbol_name":"Alvotech","start_time":0,"source_url":"","article_id":"1197124717","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197124717","pubTimestamp":1763010036,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Alvotech (NASDAQ: ALVO) plunged 7.68% on Wednesday following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALVO":"Alvotech"},"translate_title":"个股追踪|Q3营收未达预期下调指引后Alvotech股价暴跌7.68%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":1},"content_text":"Shares of Alvotech (NASDAQ: ALVO) plunged 7.68% on Wednesday following the company's disappointing third-quarter earnings report and reduced full-year guidance. The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million.\nDespite reporting a 24% increase in nine-month revenue to $420 million, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million. Adding to investor concerns, Alvotech highlighted ongoing issues from an FDA inspection of its Reykjavik facility in July as a \"top priority,\" although the facility remains FDA approved and continues production.\nThe sharp stock decline also reflects apprehension over Alvotech's cash position, which decreased to $42.8 million as of September 30. This reduction was attributed to inventory build-up for new launches, capital expenditures, and recent acquisitions. While the company secured a new $100 million working capital option to address these needs, the cash burn rate appears to be worrying investors. Despite these challenges, Alvotech reported positive developments, including new biosimilar approvals in Japan and Europe, which may provide growth opportunities in the future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197124717","isCrawlerRequest":true}